Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
- McNeil, JJ; Woods, RL; Nelson, MR; Murray, AM; Reid, CM; Kirpach, B; Storey, E; Shah, RC; Wolfe, RS; Tonkin, AM; Newman, AB; WILLIAMSON, JD; Lockery, JE; Margolis, KL; Ernst, ME; Abhayaratna, WP; Stocks, N; Fitzgerald, SM; Trevaks, RE; Orchard, SG; Beilin, LJ; Donnan, GA; Gibbs, P; Johnston, CI; Grimm, RH; Aspree Investigator Group,;
- Journal Title
- J Gerontol A Biol Sci Med Sci
- Publication Type
- Journal Article
- Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
- WEHI Research Division(s)
- Systems Biology And Personalised Medicine
- PubMed ID
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2017-04-12 10:42:16Last Modified: 2017-04-12 11:24:04